B2M and cancer: Two of the four selected TCRs (TCR1, TCR4) resulted in significant increases in the activation marker CD69 when specifically co-cultured with B2M-transduced, HLA class I-expressing cells but not control or HLA-A2 transduced cancer cells (Figure 4E–F, Figure S13).